The objective of this study was to evaluate the predictive performance of interspecies scaling of oligonucleotides to predict clearance and volume of distribution at steady state in humans from animal data. The human pharmacokinetic parameters were predicted using 1, 2, or at least 3 animal species. The results of the study indicated that the pharmacokinetic parameters of oligonucleotides can be predicted with reasonable accuracy in humans when at least 3 animal species are employed. On the other hand, allometric scaling based on 1 or 2 species or fixed coefficient or fixed exponent can be erratic and unreliable. Further work should be conducted in this direction.
Get full access to this article
View all access options for this article.
References
1.
BOXENBAUMH.1982. Comparative pharmacokinetics of benzodiazepines in dog and man. J. Pharmacokinet. Biopharm., 10:411–426.
2.
BOXENBAUMH.1984. Interspecies pharmacokinetic scaling and the evolutionary—comparative paradigm. Drug Metab. Rev., 15:1071–1121.
3.
BOXENBAUMH., DILEAC.1995. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol., 35:957–966.
4.
BOXENBAUMH., D'SOUZAR.W.1990. Interspecies pharmacokinetic scaling, biological design and neoteny. Adv. Drug Res., 19:139–196.
5.
CALDWELLG.W., MASCUSSIJ.A., YANZ., HAGEMANW.2004. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet., 29:133–143.
6.
CHAPPELLW.R., MORDENTIJ.1991. Extrapolation of toxicological and pharmacological data from animals to humans. Adv. Drug Res., 20:1–116.
7.
CUNNINGHAMC.C., HOLMLUNDJ.T., GEARYR.S., KWOHT.J., DORRA., JOHNSTONJ.F., MONIAB., NEMUNAITISJ.2001. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer, 92:1265–1271.
8.
DAIG., WEIX., LIUZ., LIUS., MARCUCCIG., CHANK.K.2005. Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 825:201–213.
9.
GEARYR.S.2009. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metabol. Toxicol., 5:381–391.
GEARYR.S., YUR.Z., WATANABET.A., HENRYS.P., HARDEEG.E., CHAPPELLA., MATSONJ., SASMORH., CUMMINSL., LEVINA.A.2003. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos., 31:1419–1428.
12.
GLOVERJ.M., LEEDSJ.M., MANTT.G., AMIND., KISNERD.L., ZUCKERMANJ.E., GEARYR.S., LEVINA.A., SHANAHANW.R.JR.1999. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)J. Pharmacol. Exp. Ther., 282:1173–1180.
13.
GOTETIK., GARNERC.E., MAHMOODI.2010. Prediction of human drug clearance from two species: a comparison of several allometric methods. J. Pharm. Sci., 99:1601–1613.
14.
GRINDELJ.M., MUSICKT.J., JIANGZ., ROSKEYA., AGRAWALS.1998. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev., 8:43–52.
15.
MAHMOODI.2004. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. Pharm. Sci., 93:177–185.
16.
MAHMOODI.2005. Interspecies scaling of clearance. Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Pine House Publishers: Rockville, MD, 39–85.
17.
MAHMOODI.2009a. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J. Pharm. Sci., 98:3850–3861.
18.
MAHMOODI.2009b. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol. Drug Interact., 24:57–81.
19.
MAHMOODI., GREENM.D., FISHERJ.E.2003. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J. Clin. Pharmacol., 43:692–697.
20.
MARCUCCIG., STOCKW., DAIG., KLISOVICR.B., LIUS., KLISOVICM.I., BLUMW., KEFAUVERC., SHERD.A., GREENM., MORANM., MAHARRYK., NOVICKS., BLOOMFIELDC.D., ZWIEBELJ.A., LARSONR.A., GREVERM.R., CHANK.K., BYRDJ.C.2005. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol., 23:3404–3411.
21.
NEMUNAITISJ., HOLMLUNDJ.T., KRAYNAKM., RICHARDSD., BRUCEJ., OGNOSKIEN., KWOHT.J., GEARYR., DORRA., VON HOFFD., ECKHARDTS.G.1999. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol., 17:3586–3595.
22.
RAYNAUDF.I., ORRR.M., GODDARDP.M., LACEYH.A., LANCASHIREH., JUDSONI.R., BECKT., BRYANB., COTTERF.E.1997. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther., 281:420–427.
23.
REIGNERB.G., BLESCHK.S.2002. Estimating the starting dose for entry into humans: principles and practice. Eur. J. Clin. Pharmacol., 57:835–845.
24.
SEWELLK.L., GEARYR.S., BAKERB.F., GLOVERJ.M., MANTT.G., YUR.Z., TAMIJ.A., DORRF.A.2002. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther., 303:1334–1343.
25.
STEVENSONJ.P., YAOK.S., GALLAGHERM., FRIEDLANDD., MITCHELLE.P., CASSELLAA., MONIAB., KWOHT.J., YUR., HOLMLUNDJ., DORRF.A., O'DWYERP.J.1999. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J. Clin. Oncol., 17:2227–2236.
26.
TANGH., HUSSAINA., LEALM., MAYERSOHNM., FLUHLERE.2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab. Dispos., 35:1886–1893.
27.
YUR.Z., GEARYR.S., LEEDSJ.M., WATANABET., MOOREM., FITCHETTJ., MATSONJ., BURCKINT., TEMPLINM.V., LEVINA.A.2001. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci., 90:182–193.
28.
YUR.Z., KIMT.W., HONGA., WATANABET.A., GAUSH.J., GEARYR.S.2007. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos., 35:460–468.
29.
ZHANGR., DIASIOR.B., LUZ., LIUT., JIANGZ., GALBRAITHW.M., AGRAWALS.1995a. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol., 49:929–939.
30.
ZHANGR., YANJ., SHAHINIANH.K., AMING., LUZ., LIUT., SAAGM.S., JIANGZ., TEMSAMANIJ., MARTINR.R.1995b. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther., 58:44–53.
